The odds for and against betting on Provention Bio’s (Nasdaq: PRVB) teplizumab, which is being studied in the prevention of type 1 diabetes (T1D) among at-risk patients, have been assessed.
Analysts at RBC Capital Markets have rated Provention Bio with an Outperform rating, and a key opinion leader (KOL) in medicine is cited in a RBC report as expressing mixed views about the prospects of teplizumab.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze